The effects of mifepristone on uterine sensitivity to oxytocin and on fetal heart rate patterns. 2001

P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
Department of Obstetrics and Gynecology, Hôpital Arnaud de Villeneuve, University of Montpellier, 371 rue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France. pl-giacalone@chu-montpellier.fr

OBJECTIVE To compare the incidences of tachysystole, hypertonia and fetal heart rate (FHR) abnormalities in women treated by mifepristone plus prostaglandins (PGs), mifepristone alone or PGs alone for an unfavourable cervix. METHODS In this retrospective study, all women between 37 and 42 weeks were eligible for the study if they had undergone cervical ripening prior to labour induction. In group 1, the women were treated with mifepristone plus PGs (n=103). Group 2 women were treated with mifepristone alone (n=96) and group 3 women with PGs alone (n=100). Incidences of tachysystole, hypertonia and FHR abnormalities were compared. RESULTS During induction of labour, tachysystole and hypertonia occurred more frequently in women treated with mifepristone. Severe bradycardia and recurrent late decelerations were more frequent after the initiation of oxytocin in groups 1 and 2 than in group 3. CONCLUSIONS In this study, mifepristone increased the incidences of tachysystole, hypertonia and FHR abnormality.

UI MeSH Term Description Entries
D007751 Labor, Induced Artificially induced UTERINE CONTRACTION. Induced Labor,Induction of Labor,Labor Induced,Labor Induction,Induced, Labor,Induction, Labor,Inductions, Labor,Labor Inductions
D010121 Oxytocin A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. Ocytocin,Pitocin,Syntocinon
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D001919 Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK. Bradyarrhythmia,Bradyarrhythmias,Bradycardias
D005260 Female Females
D005865 Gestational Age The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated from the onset of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization. It is also estimated to begin from fertilization, estrus, coitus, or artificial insemination. Embryologic Age,Fetal Maturity, Chronologic,Chronologic Fetal Maturity,Fetal Age,Maturity, Chronologic Fetal,Age, Embryologic,Age, Fetal,Age, Gestational,Ages, Embryologic,Ages, Fetal,Ages, Gestational,Embryologic Ages,Fetal Ages,Gestational Ages
D006340 Heart Rate, Fetal The heart rate of the FETUS. The normal range at term is between 120 and 160 beats per minute. Fetal Heart Rate,Fetal Heart Rates,Heart Rates, Fetal,Rate, Fetal Heart,Rates, Fetal Heart
D006727 Hormone Antagonists Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. Antagonists, Hormone

Related Publications

P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
July 2008, American journal of obstetrics and gynecology,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
February 1978, American journal of obstetrics and gynecology,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
January 1999, Journal of nurse-midwifery,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
May 2004, The Journal of reproductive medicine,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
August 2007, European journal of obstetrics, gynecology, and reproductive biology,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
October 1972, Geburtshilfe und Frauenheilkunde,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
October 1995, American journal of obstetrics and gynecology,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
April 1972, The Journal of obstetrics and gynaecology of the British Commonwealth,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
July 1977, British journal of obstetrics and gynaecology,
P L Giacalone, and J P Daurés, and J M Faure, and P Boulot, and B Hedon, and F Laffargue
May 1997, Early human development,
Copied contents to your clipboard!